Article (Scientific journals)
Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
Millot, F; Suciu, S; Philippe, N et al.
2001In Journal of Clinical Oncology, 19, p. 1935-1942
Peer Reviewed verified by ORBi
 

Files


Full Text
18 Milllot.pdf
Publisher postprint (6.27 MB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Abstract :
[en] PURPOSE: The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen. PATIENTS AND METHODS: After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B). RESULTS: Between January 1990 and January 1996, 653 patients with ALL (593 patients) or lymphoblastic lymphoma (60 patients) were randomized: 323 were assigned to Arm A (without Ara-C) and 330 to Arm B (with Ara-C). A total of 190 events (177 relapses and 13 deaths without relapse) were reported, and the median follow up was 6.5 years (range, 2 to 10 years). The incidence rates of CNS relapse were similar in both arms whether isolated (5.6% and 3.3%, respectively) or combined (5.3% and 4.6%, respectively). The estimated 6-year disease-free survival (DFS) rate was similar (log-rank P =.67) in the two treatment groups: 70.4% (SE = 2.6%) in Arm A and 71.0% (SE = 2.5%) in Arm B. The 6-year DFS rate was similar for ALL and LL patients: 70.2% (SE = 1.9%) versus 76.3% (SE = 5.6%). CONCLUSION: Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted. Disappointingly, with the dose schedule used in this protocol, HD Ara-C added to HD MTX, although well tolerated, failed to further decrease the incidence of CNS relapse or to improve the overall DFS.
Disciplines :
Hematology
Pediatrics
Author, co-author :
Millot, F
Suciu, S
Philippe, N
Benoit, Y
Mazingue, F
Uyttebroeck, A
Lutz, P
Mechinaud, F
Robert, A
Boutard, P
Marguerite, G
Ferster, A
Plouvier, E
Rialland, X
Behard, C
Plantaz, D
DRESSE, Marie-Françoise ;  Centre Hospitalier Universitaire de Liège - CHU > Service de pédiatrie
Philippet, P
Norton, L
Thyss, A
Dastungue, N
Waterkeyn, C
Vilmer, E
Otten, J
More authors (14 more) Less
Language :
English
Title :
Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
Publication date :
2001
Journal title :
Journal of Clinical Oncology
ISSN :
0732-183X
eISSN :
1527-7755
Publisher :
American Society of Clinical Oncology, Alexandria, United States - Virginia
Volume :
19
Pages :
1935-1942
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 31 May 2016

Statistics


Number of views
214 (5 by ULiège)
Number of downloads
303 (0 by ULiège)

Scopus citations®
 
50
Scopus citations®
without self-citations
37
OpenCitations
 
48

Bibliography


Similar publications



Contact ORBi